Clinical event committees in coronary stent trials: Insights and recommendations based on experience in an unselected study population

EuroIntervention

Volumn 8, Issue 3, 2012, Pages 368-374

  Vranckx, Pascal ^a   McFadden, Eugene ^b   Mehran, Roxana ^c   Cutlip, Donald E ^d  

^a Clinical Research Management and Core Laboratories   (Netherlands)

^b Department of Medicine National University of Ireland Cork   (Ireland)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Clinical event committee; Coronary; Endpoints; Stenting

Indexed keywords

BIOLOGICAL MARKER; CREATINE KINASE; CREATINE KINASE MB; TROPONIN;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ARTICLE; CAUSE OF DEATH; CLINICAL EVENT COMMITTEE; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG ELUTING STENT; HEART INFARCTION; HEART MUSCLE NECROSIS; HUMAN; IN-STENT RESTENOSIS; INFORMATION PROCESSING; PATIENT MONITORING; PATIENT SELECTION; PROFESSIONAL STANDARD; QUALITY CONTROL; REOPERATION; STENT THROMBOSIS; STUDY DESIGN; WORK EXPERIENCE;

ANGIOPLASTY, BALLOON, CORONARY; CLINICAL TRIALS AS TOPIC; DATA COLLECTION; ENDPOINT DETERMINATION; HUMANS; MYOCARDIAL INFARCTION; PEER REVIEW, RESEARCH; STENTS; THROMBOSIS;

EID: 84872086285     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV8I3A56     Document Type: Article

References (19)

1. Krucoff MW, Mehran R, van Es GA, Boam A, Cutlip D. The Academic Research Consortium (ARC) Governance Charter. JACC Cardiovasc Interv. 2011;4:595-6.
2. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-2351.
3. de Boer SP, Lenzen MJ, Oemrawsingh RM, Simsek C, Duckers HJ, van der Giessen WJ, Serruys PW, Boersma E. Evaluating the 'all-comers' design: a comparison of participants in two 'all-comers' PCI trials with non-participants. Eur Heart J. 2011;32:2161-7.
4. Serruys PW, SilberS, Garg S van Geuns RJ, Richardt G, Buszman PE, Kelbæk H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, M.D., DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S. Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents. N Engl J Med. 2010;363:123-135.
5. Silber S, Windecker S, Vranckx P, Serruys PW; RESOLUTE All Comers Investigators. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet. 2011;377:1241-7.
6. Slutsky AS, Lavery JV. Data safety and monitoring boards. N Engl J Med. 2004;350:1143-7.
7. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010;375:201-9.
8. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Juni P. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet. 2008;372:1163-73.
9. Vranckx P, Cutlip DE, Mehran R, Kint PP, Silber S, Windecker S, Serruys PW. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. EuroIntervention. 2010;5:871-874.
10. Cutlip DE, Nakazawa G, Krucoff MW, Vorpahl M, Mehran R, Finn AV, Vranckx P, Kimmelstiel C, Berger C, Petersen JL, Palabrica T, Virmani R. Autopsy validation study of the academic research consortium stent thrombosis definition. JACC Cardiovasc Interv. 2011;4:554-9.
11. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation.1979;59:607-9.
12. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J. 2007;28:2525-38.
13. Grines CL, Dixon S. A nail in the coffin of troponin measurements after percutaneous coronary intervention. J Am Coll Cardiol. 2011;57:662-3.
14. Lim CC, van Gaal WJ, Testa L, Cuculi F, Arnold JR, Karamitsos T, Francis JM,Petersen SE, Digby JE, Westaby S, Antoniades C, Kharbanda RK, Burrell LM, Neubauer S, Anning AP. With the "universal definition," measurement of creatine kinase myocardial band rather than troponin allows more accurate diagnosis of periprocedural necrosis and infarction after coronary intervention. J Am Coll Cardiol. 2011;57:653-61.
15. Prasad A, Herrmann J. Myocardial Infarction Due to Percutaneous Coronary Intervention. N Engl J Med. 2011;364:453-64.
16. Vranckx P, Cutlip DE, Mehran R, Kint PP, Silber S, Windecker S, Serruys PW. Myocardial Infarction adjudication in Contemporary All-Comer Stent trials: Balancing sensitivity and specificity. Addendum to the Historical MI definitions used in stent studies. EuroIntervention. 2010;5:871-874.
17. Califf RM, Abdelmeguid AE, Kuntz RE, Popma JJ, Davidson CJ, Cohen EA, Kleiman NS, Mahaffey KW, Topol EJ, Pepine CJ, Lipicky RJ, Granger CB, Harrington RA, Tardiff BE, Crenshaw BS, Bauman RP, Zuckerman BD, Chaitman BR, Bittl JA, Ohman EM. Myonecrosis after revascularization procedures. J Am Coll Cardiol. 1998;31:241-51.
18. Ellis SG, Chew D, Chan A, Whitlow PL, Schneider JP, Topol EJ. Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation. 2002;106:1205-10.
19. Stone GW, Mehran R, Dangas G, Lansky AJ, Kornowski R, Leon MB. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. Circulation. 2001;104:642-67.